Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MEDVidi vs Spry

MEDVidi
Graded #384

Higher grade

vs+1.2000000000000028
Spry
Graded #408

Lower grade

The verdict

MEDVidi takes it — 58/100 to 56.8/100, but only just.

MEDVidi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus… Spry is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSpry +9
45
54
Dose & formulationSpry +11
53
64
Clinical oversightMEDVidi +22
77
55
Labs & monitoringMEDVidi +10
62
52
FulfillmentSpry +2
59
61
Contract termsEven
55
55
MEDVidi · left barSpry · right bar

The numbers

MetricMEDVidiSpry
WeighScore58/10056.8/100
GradeCC
Scorecard rank#384#408
SemaglutideNot disclosed$199/mo (starting dose, compounded)
TirzepatideNot disclosed$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
MEDVidi

Graded #384 · C

Strengths

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where it loses points

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated
Spry

Graded #408 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard